Breaking News, Collaborations & Alliances

WuXi Advanced Therapies Enters Licensing Agreement with Janssen

WuXi ATU will license its TESSA technology used for producing adeno-associated viral (AAV) vectors.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

WuXi Advanced Therapies (WuXi ATU), a contract testing, development and manufacturing organization (CTDMO), entered a licensing agreement with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Under this agreement, WuXi ATU will license to Janssen its TESSA technology, a high-performance system that can produce 10 times more adeno-associated viral (AAV) vectors than traditional AAV manufacturing systems, according to WuXi. Janssen will also have access to wor...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters